Company Overview and News

1
LMNR / Limoneira Co. 10-Q (Quarterly Report)

2018-09-10 sec.gov
Document LIMONEIRA COMPANY
LMNR

2
LMNR / Limoneira Co. 8-K (Current Report)

2018-09-10 sec.gov - 1
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LMNR

1
Pick Up Shares Of Limoneira

2018-08-07 seekingalpha
California droughts have sent lemon prices - and shares of LMNR - higher in recent weeks.
LMNR

2
LMNR / Limoneira Co. FORM 8-K (Current Report)

2018-07-27 sec.gov - 1
UNITED STATES
LMNR

130
Top Analyst Upgrades and Downgrades: CBS, Disney, Regions Financial, Salesforce, T-Mobile and Many More

2018-06-28 247wallst
The futures traded down again Thursday morning, and it appears that the back and forth trading on Wednesday wore down investors. Once again, the trade and tariff issues were cited as the main reason. Oil jumped again, sparked by a big drop in crude inventories, closing up over 2.5%. With summer vacations in full swing and Americans hitting the road in record numbers to celebrate the fourth of July, you can bet there may be some added pain at the pump.
CBS CBS.A ANGI FLXN RF LMNR CBS.WD ATSG CRM BF.B BF.A BFA TRI CPV MS

1
LMNR / Limoneira Co. FORM 8-K (Current Report)

2018-06-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LMNR

4
Limoneira Summer 2018 Update

2018-06-26 seekingalpha - 1
The investment thesis for the company is still intact. Should the dilutive event cause Limoneira to sell off to the low $20s, it would offer a solid price to buy shares.
CVGW ALHVS LWSGY LMNR LWSGF

1
LMNR / Limoneira Co. FORM 8-K (Current Report)

2018-06-25 sec.gov
UNITED STATES
LMNR

1
LMNR / Limoneira Co. FINAL PROSPECTUS SUPPLEMENT (Prospectus)

2018-06-22 sec.gov
tv496927_424b5 - none - 3.2921186s TABLE OF CONTENTS
LMNR

2
LMNR / Limoneira Co. PRELIMINARY PROSPECTUS SUPPLEMENT (Prospectus)

2018-06-20 sec.gov - 1
tv496652_424b5 - none - 23.384687s TABLE OF CONTENTS
LMNR

2
LMNR / Limoneira Co. FORM 8-K (Current Report)

2018-06-20 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LMNR

1
LMNR / Limoneira Co. 10-Q (Quarterly Report)

2018-06-11 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LMNR

4
LMNR / Limoneira Co. FORM 8-K (Current Report)

2018-06-11 sec.gov - 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washingto
LMNR

1
LMNR / Limoneira Co. FORM 8-K (Current Report)

2018-05-17 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
LMNR

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 532746104